Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.30 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989684 | 0.83 | HSD11B1 (0.33) | HSD11B1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL988889 | 0.82 | POLB (0.33) | HSD11B1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL988941 | 0.81 | HSD11B1 (0.31) | HSD11B1SLC6A2SLC6A4SLC6A3DAGLB | |
| SCHEMBL4255610 | 0.79 | MAOA (0.40) | HSD11B1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL990532 | 0.78 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL989616 | 0.77 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL989046 | 0.76 | SLC6A2 (0.47) | HSD11B1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL989723 | 0.74 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL988871 | 0.74 | SLC6A2 (0.39) | HSD11B1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL990296 | 0.73 | HSD11B2 (0.45) | HSD11B1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | HSD11B1 1303/4885SLC6A2 49/4885SLC6A4 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.